|Home | About | Journals | Submit | Contact Us | Français|
Microenvironment-based alterations in phenotypes of mast cells influence the susceptibility to anaphylaxis, yet the mechanisms underlying proper maturation of mast cells toward an anaphylaxis-sensitive phenotype are incompletely understood. Here we report that PLA2G3, a mammalian homolog of anaphylactic bee venom phospholipase A2, regulates this process. PLA2G3 secreted from mast cells is coupled with fibroblastic lipocalin-type PGD2 synthase (L-PGDS) to provide PGD2, which facilitates mast-cell maturation via PGD2 receptor DP1. Mice lacking PLA2G3, L-PGDS or DP1, mast cell–deficient mice reconstituted with PLA2G3-null or DP1-null mast cells, or mast cells cultured with L-PGDS–ablated fibroblasts exhibited impaired maturation and anaphylaxis of mast cells. Thus, we describe a lipid-driven PLA2G3–L-PGDS–DP1 loop that drives mast cell maturation.
Anaphylaxis is a serious immediate allergic reaction that involves the activation of mast cells. Cross-linking of the high-affinity IgE receptor FcεRI on mast cells with IgE and antigen initiates signals leading to the release of allergic mediators that induce immediate hypersensitivity1. Anaphylaxis is triggered by allergens (for example, insect venom, food and medication) and damages multiple organs including the respiratory and circulatory systems, often leading to life-threatening episodes.
Environmentally induced alterations in phenotypes of mast cells could be one factor that influences the severity of anaphylaxis. Current evidence has established the essential role of stem cell factor (SCF) and its receptor c-Kit (CD117) for development of mast cells2. However, the SCF–c-Kit system alone is insufficient to drive the maturation of mast cells fully, as culture of immature mast cells with fibroblasts, but not with SCF alone, can induce differentiation into mature mast cells2. Although several cytokines, chemokines and adhesion molecules have supporting roles in tissue-specific homing, growth or differentiation of mast cells3–7, precise mechanisms underlying mast cell–fibroblast communication leading to optimal maturation of mast cells still remain elusive.
Lipid mediators, such as prostaglandins, leukotrienes and lysophospholipids, have important roles in various biological processes, including allergy8–15. A given lipid mediator (for example, PGD2) aggravates, suppresses or resolves allergic responses11–13, and this functional variability may depend on the use of distinct biosynthetic enzyme and/or receptor subtypes in different cells. Eicosanoid biosynthesis is initiated by release of arachidonic acid from phospholipids by phospholipase A2 (PLA2) enzymes16. PLA2G4A (cytosolic PLA2; cPLA2α) has an essential role in the generation of eicosanoids in various cells, and its deletion results in diminished airway hypersensitivity17. By contrast, the role of secreted PLA2 (sPLA2) enzymes is still a subject of debate. Although the lower asthmatic responses in mice lacking two classical sPLA2 enzymes (PLA2G5 and PLA2G10) have revealed their contribution to asthma18,19, the mechanisms underlying the actions of these enzymes remain poorly understood.
A major bee venom component responsible for anaphylaxis is an atypical form of sPLA2 called BV-PLA220,21. The mammalian genome encodes group III sPLA2 (PLA2G3), which is the sole homolog of BV-PLA216,22–26. Here we provide evidence that PLA2G3 is a major mast cell granule-associated sPLA2 that facilitates the maturation of mast cells by driving a previously unrecognized lipid mediator circuit. PLA2G3 released from mast cells is coupled with fibroblast lipocalin-type PGD synthase (L-PGDS) to provide PGD2, which then acts on type-1 PGD receptor, DP1, induced on mast cells to promote their maturation.
When injected intradermally into the mouse ear pinnas, BV-PLA2 or human PLA2G3 alone induced a similar, dose-dependent vascular leak and augmented passive cutaneous anaphylaxis (PCA) induced by IgE and antigen in Kit+/+ mice but not in mast cell–deficient KitW-sh/W-sh mice, in which the SCF receptor c-Kit has a substitution (Fig. 1a,b). The edema induced by PLA2G3 was accompanied by ultrastructural degranulation of dermal mast cells (Fig. 1c). PLA2G3 induced the release of histamine (Fig. 1d), but not of lactate dehydrogenase (Supplementary Fig. 1a), from mouse peritoneal mast cells (pMCs) in a Ca2+-dependent manner, indicating that PLA2G3 elicits degranulation, not cell lysis.
Immunohistochemistry analysis revealed that PLA2G3 localized with toluidine blue+ dermal mast cells in wild-type mice but not in Pla2g3−/− mice22 (Fig. 1e). Punctate staining in resting mast cells and sparse staining in degranulated mast cells suggest that PLA2G3 is released upon degranulation (Fig. 1e,f). In bone marrow–derived cell populations, Pla2g3 mRNA was more highly enriched in IL-3–driven bone marrow–derived mast cells (BMMCs) and thymic stromal lymphopoietin (TSLP)-driven bone marrow–derived basophils (BM basophils) than in GM-CSF–driven bone marrow–derived dendritic cells (BMDCs) and M-CSF–driven bone marrow–derived macrophages (BMDMs), and was undetectable in Swiss 3T3 fibroblasts (Fig. 1g and Supplementary Fig. 1b). Of the mRNAs encoding sPLA2 isoforms, Pla2g3 mRNA was expressed most abundantly in BMMCs, followed by Pla2g5 and Pla2g2e, whereas mRNAs encoding the other sPLA2 isoforms were undetectable, and SCF-fibroblast–driven maturation of these cells toward connective tissue mast cells (CTMCs) did not affect the expression of these sPLA2 enzymes (Supplementary Fig. 1c). When we transfected rat mastocytoma RBL-2H3 cells with cDNA encoding PLA2G3 or a catalytically inactive PLA2G3 variant, III-HQ, in which the catalytic-center histidine was replaced with asparagine23, release of β-hexosaminidase (β-HEX) and generation of PGD2 induced by crosslinking of FcεRI by IgE and antigen (hereafter called IgE-Ag) was augmented in cells overexpressing native PLA2G3 but not catalytically inactive PLA2G3 (Supplementary Fig. 1d). Thus, PLA2G3 is the main sPLA2 in mouse mast cells, is released by exocytosis and can augment activation of mast cells in a manner dependent upon its enzymatic activity.
Upon passive systemic anaphylaxis (PSA) induced by IgE-Ag, Pla2g3+/+ and WBB6F1-Kit+/+ mice, but not mast cell–deficient WBB6F1-KitW/W-v mice, had much more plasma histamine and a temporary decrease in rectal temperature after systemic antigen challenge, whereas these responses were mild in Pla2g3−/− mice (Fig. 2a). Upon PCA induced by IgE-Ag (Fig. 2b and Supplementary Fig. 1e) or compound 48/80 (C48/80; Fig. 2c), edema was markedly lower in Pla2g3−/− mice than Pla2g3+/+ mice. By contrast, transgenic overexpression of human PLA2G3 (PLA2G3tg/+)26 augmented both IgE-Ag–dependent (Fig. 2d and Supplementary Fig. 1e) and C48/80-induced (Fig. 2e) PCA as well as IgE-Ag–induced PSA (Fig. 2f). Although the ear skin of Pla2g3−/− and Pla2g3+/+ mice contained an equivalent number of toluidine blue+ mast cells, we detected fewer cells showing signs of IgE-Ag–induced degranulation in Pla2g3−/− mice than in Pla2g3+/+ mice (Fig. 2g). Conversely, ears of IgE-Ag–treated PLA2G3tg/+ mice had more degranulated mast cells than those of replicate control mice despite a similar total mast cell count (Fig. 2h). IgE-Ag–induced PCA in mice lacking other sPLA2 enzymes (Pla2g2d−/−, Pla2g2e−/−, Pla2g2f−/−, Pla2g5−/− and Pla2g10−/−) was similar to that in respective wild-type littermates (Supplementary Fig. 1f).
We immunized Pla2g3+/+ and Pla2g3−/− mice intraperitoneally with alum-adsorbed ovalbumin (OVA) and elicited active cutaneous anaphylaxis by intradermal injection of OVA, which cross-links endogenous IgE-bound FcεRI on mast cells. Under conditions in which serum anti-OVA IgE levels were similar in both genotypes, Pla2g3−/− mice exhibited lower local anaphylaxis than did Pla2g3+/+ mice, as indicated by notable reductions in ear swelling and mast cell degranulation (Fig. 2i–k). Thus, PLA2G3 is the sole sPLA2 isoform associated with mast cell–dependent anaphylaxis.
Transmission electron microscopy analysis revealed that resting mast cells in Pla2g3+/+ mice were oval with regular short processes and had many secretory granules filled with electron-lucent and dense contents, whereas those in Pla2g3−/− mice had unusual granules that were small and irregular in size, suggesting the immaturity of mast cells (Fig. 3a and Supplementary Fig. 2a). After challenge with antigen, Pla2g3+/+ skin mast cells exhibited features typical of degranulation, whereas Pla2g3−/− mast cells were almost insensitive. In agreement, the amount of histamine (Fig. 3b) and the expression of Hdc (which encodes histidine decarboxylase, a histamine-biosynthetic enzyme; Fig. 3c) were lower in the ears of Pla2g3−/− mice than in those of Pla2g3+/+ mice. Enzymatic activity (Fig. 3d) and expression (Fig. 3e) of mast cell proteases, including chymase (encoded by Mcpt4), tryptase (encoded by Mcpt6) and carboxypeptidase (encoded by Cpa3), were also notably lower in the ears of Pla2g3−/− mice relative to Pla2g3+/+ mice. However, expression of Kit, Mitf (which encodes a transcription factor essential for mast cell differentiation) and Srgn (which encodes serglycin, a proteoglycan core protein) was unchanged in ears of Pla2g3−/− mice (Fig. 3e), indicating that not all mast cell markers were affected by PLA2G3 deficiency. We confirmed the lower expression of HDC and the unaltered expression of c-Kit in the skin of Pla2g3−/− mice by immunoblotting (Fig. 3f).
Pla2g3−/− pMCs also had smaller and more irregular granules (Fig. 3g and Supplementary Fig. 2b), contained less histamine (Fig. 3h) and exhibited less IgE-Ag–induced histamine release (both amount and percentage; Fig. 3i) than Pla2g3+/+ pMCs. Although the proportion of Kit+FcεRIα+ skin mast cells or pMCs was similar in both genotypes, surface expression of FcεRIα was lower in Pla2g3−/− mice than in Pla2g3+/+ mice (Supplementary Fig. 2c,d). A23187-induced histamine release by Pla2g3−/− pMCs was lower in terms of amount, but not percentage, compared to that by Pla2g3+/+ pMCs (Supplementary Fig. 2e), suggesting that the attenuated IgE-Ag–induced degranulation and anaphylaxis in Pla2g3−/− mice was mainly due to the lower histamine content and surface FcεRI expression. Furthermore, intestinal expression of Mcpt1 and Mcpt2 (which encode mucosal mast-cell proteases) was markedly lower in Pla2g3−/− mice than in Pla2g3+/+ mice (Supplementary Fig. 2f). Thus, the lower anaphylaxis in Pla2g3−/− mice may result from abnormalities in the maturation and degranulation of mast cells in multiple anatomical sites. Other immune-cell populations in the skin and spleen were unaffected by PLA2G3 deficiency (Supplementary Fig. 2g,h).
To assess whether the aberrant features of mast cells in Pla2g3−/− mice relied on the absence of PLA2G3 in the mast cells themselves or in mast cell microenvironment, we transferred Pla2g3+/+ or Pla2g3−/− BMMCs intradermally into mast cell–deficient KitW-sh/W-sh mice. After 6 weeks, the distribution of mast cells in the ear dermis was comparable between mice reconstituted with Pla2g3+/+ BMMCs and those reconstituted with Pla2g3−/− BMMCs (Supplementary Fig. 3a). Expression of mast-cell marker genes Hdc, Mcpt4, Mcpt6 and Cpa3 (Fig. 3j) and IgE-Ag–mediated PCA (Fig. 3k and Supplementary Fig. 3b) was much greater in the ears of mice that received Pla2g3+/+ BMMCs over control KitW-sh/W-sh mice, whereas these changes were scarcely seen in mice that received Pla2g3−/− BMMCs. We observed similar results when we transferred Pla2g3+/+ or Pla2g3−/− BMMCs intravenously into KitW-sh/W-sh mice. After 12 weeks of reconstitution, IgE-Ag–mediated PCA was restored in mice reconstituted with Pla2g3+/+ BMMCs but remained poor in mice reconstituted with Pla2g3−/− BMMCs, although we observed similar numbers of reconstituted mast cells in the ear dermis (Supplementary Fig. 3c,d). In these experiments, low levels of mast-cell engraftment in the skin of KitW-sh/W-sh mice relative to baseline amounts in the skin of wild-type mice restored PCA efficiently. KitW-sh/W-sh mice transferred with PLA2G3tg/+ BMMCs had a greater PCA response compared to those transferred with control BMMCs (Supplementary Fig. 3e). Altogether, the defective maturation and activation of mast cells in Pla2g3−/− mice are cell autonomous, even though the migration of mast cell progenitors into extravasuclar tissues is not profoundly impaired by PLA2G3 deficiency.
Pla2g3−/− BMMCs grew normally in medium supplemented with IL-3 (Supplementary Fig. 4a) and, unlike tissue-resident mast cells, they had normal surface expression of FcεRIα (Supplementary Fig. 4b). Stimulation with IgE-Ag induced a robust release of sPLA2 activity from wild-type BMMCs, whereas this release was ablated in Pla2g3−/− BMMCs and augmented in PLA2G3tg/+ BMMCs (Supplementary Fig. 4c,d), confirming that PLA2G3 is released upon degranulation. IgE-Ag–stimulated Pla2g3−/− BMMCs released less histamine, PGD2 and LTC4 than Pla2g3+/+ BMMCs, whereas these responses were greater in PLA2G3tg/+ BMMCs than in control BMMCs (Supplementary Fig. 4e–j). IgE-Ag–induced influx of Ca2+, induction of cytokines (encoded by Il4, Il6 and Tnf) and phosphorylation of phospholipase C (PLCγ2) and Akt were similar between the genotypes (Supplementary Fig. 4k–m), suggesting that FcεRI-dependent signaling was not profoundly perturbed by PLA2G3 deficiency. Generation of eicosanoids by mast cells depends on cPLA2α, which is regulated by Ca2+-dependent membrane translocation and MAP kinase-directed phosphorylation17. Consistent with the lower generation of eicosanoids (Supplementary Fig. 4f,g), FcεRI-dependent phosphorylation of ERK (not JNK and p38) and cPLA2α and decrease in arachidonic acid–containing phosphatidylcholine were partially impaired in Pla2g3−/− BMMCs compared to Pla2g3+/+ BMMCs, despite the equivalent expression of total ERK and cPLA2α proteins in both cells (Supplementary Fig. 4m–o). Thus, PLA2G3 deficiency attenuates activation of ERK and cPLA2α in BMMCs.
We took advantage of an in vitro system in which immature BMMCs undergo maturation toward mature CTMC-like cells in coculture with Swiss 3T3 fibroblasts27. PLA2G3 deficiency did not affect the proliferation of BMMCs in coculture (Supplementary Fig. 5a). During coculture, sPLA2 activity was secreted from wild-type BMMCs in response to SCF, whereas sPLA2 secretion was absent in Pla2g3−/− BMMCs and augmented in PLA2G3tg/+ BMMCs (Fig. 4a,b). Although the ultrastructure of Pla2g3−/− BMMCs appeared normal, Pla2g3−/− CTMC-like cells contained unusual granules with less electron-dense contents than did Pla2g3+/+ CTMC-like cells (Fig. 4c and Supplementary Fig. 5b). After coculture, the expression of Hdc (Fig. 4d) and its product histamine (Fig. 4e) were markedly greater in Pla2g3+/+ CTMC-like cells, whereas these changes were barely seen in Pla2g3−/− cells. Even before coculture, Hdc expression and histamine content were slightly lower in Pla2g3−/− BMMCs than in Pla2g3+/+ BMMCs, indicating that some early developmental process had already been perturbed by PLA2G3 deficiency. IgE-Ag–induced histamine release was greater in Pla2g3+/+ cells after coculture than before coculture, whereas this coculture-driven increase in histamine release was impaired in Pla2g3−/− cells (Fig. 4f). Conversely, coculture-induced Hdc expression was greater in PLA2G3tg/+ CTMC-like cells than in control cells (Supplementary Fig. 5c). Supplementation with PLA2G3 in coculture significantly restored the histamine level in Pla2g3−/− CTMC-like cells and also elevated it in Pla2g3+/+ cells (Fig. 4g). Pla2g3−/− BMMCs without coculture did not respond to PLA2G3 (Fig. 4g), suggesting that the action of PLA2G3 on histamine synthesis in mast cells depends on fibroblasts. Histamine content in Pla2g3+/+ BMMCs without coculture was substantially lower in the presence of PLA2G3 than its absence (Fig. 4g), which might reflect that the enzyme elicits the release of prestored histamine by degranulation (Fig. 1b).
The maturation of wild-type BMMCs to CTMC-like cells increased FcεRI-dependent PGD2 synthesis (Fig. 4h), with a concomitant increase in Ptgds2 (hematopoietic PGD2 synthase; H-PGDS) (Fig. 4i). However, these changes in the PGD2 pathway occurred only weakly in Pla2g3−/− cells. Surface expression of FcεRIα was significantly elevated in Pla2g3+/+ cells but not in Pla2g3−/− cells after coculture (Supplementary Fig. 5d), consistent with the lower surface FcεRIα expression on tissue-resident mast cells in Pla2g3−/− mice. The coculture-driven induction of Mcpt4 and Mcpt6 (which encode mast cell proteases) and Ndrg1 (which encodes a mast cell granule–associated protein27) was also impaired in Pla2g3−/− cells, whereas the constitutive expression of Srgn and Kit was unaffected (Supplementary Fig. 5e). We verified the attenuated induction of HDC and H-PGDS and the unaltered expression of c-Kit in Pla2g3−/− CTMC-like cells at the protein level (Fig. 4j). Although Pla2g3+/+ CTMC-like cells acquired sensitivity to C48/80 after coculture27, C48/80-induced degranulation (Fig. 4k) and induction of the putative C48/80 receptors encoded by Mrgprx1 and Mrgprx2 (ref. 28; Supplementary Fig. 5e) after coculture were lower in Pla2g3−/− cells. The coculture-dependent decrease in Itga5 (which encodes integrin αE) and increase in Icam1 (which encodes integrin β7), which participates in tissue homing of mast-cell progenitors6, were unaffected by PLA2G3 deficiency (Supplementary Fig. 5e), consistent with the unaltered number of mast cells in Pla2g3−/− tissues. Microarray gene profiling using Pla2g3+/+ and Pla2g3−/− BMMCs before and after coculture revealed that, of the ~41,000 genes examined, Pla2g3+/+ cells expressed 3,632 coculture-inducible genes, of which 1,409 genes were barely or only partially induced in Pla2g3−/− cells. Genes affected by Pla2g3 ablation included, for example, genes associated with secretory granules, genes related to biosynthesis or receptors for lipid mediators, and genes for cytokines, chemokines and their receptors (Fig. 4l and Supplementary Table 1), underscoring the immaturity of Pla2g3−/− cells, particularly after coculture.
By comparison, Pla2g4a−/− mice exhibited normal IgE-Ag–induced PCA, with normal counts of dermal mast cells and normal amounts of histamine (Supplementary Fig. 5f–h). IgE-Ag–induced histamine release, cellular histamine content and Hdc expression were unaffected by ablation of cPLA2α (Supplementary Fig. 5i–k). Neither PGD2 nor LTC4 was produced by Pla2g4a−/− BMMCs (Supplementary Fig. 5l,m), confirming the obligatory role of cPLA2α in eicosanoid synthesis in mast cells29. Thus, the absence of mast cell–derived eicosanoids by cPLA2α deficiency did not affect maturation, degranulation and anaphylaxis of mast cells, suggesting that the effect of PLA2G3 deficiency on mast cells could not be simply explained by defective synthesis of eicosanoids by mast cells.
To identify the specific lipid-mediator pathway that lies downstream of PLA2G3, we induced IgE-Ag–dependent PCA on mouse lines deficient in various eicosanoid receptors or biosynthetic enzymes. Of the eicosanoid receptor–deficient mouse lines tested, PCA was lower only in mice lacking the PGD receptor DP1 (Ptgdr−/−)9. Vascular leakage was lower and ear mast cells exhibited poor degranulation despite an unaltered total count in Ptgdr−/− mice compared to wild-type mice (Fig. 5a,b). Dermal mast cells in Ptgdr−/− mice had fewer mature secretory granules, contained less histamine and were less sensitive to IgE-Ag–induced degranulation than those in Ptgdr+/+ mice (Fig. 5c,d). Whereas the PCA was efficiently restored in KitW-sh/W-sh mice reconstituted with Ptgdr+/+ BMMCs, it was restored only partially in those mice reconstituted with Ptgdr−/− BMMCs (Fig. 5e). The PCA was unaltered or only slightly augmented in mice lacking other eicosanoid receptors or biosynthetic enzymes (Ptgdr2−/−, Ptger1−/−, Ptger2−/−, Ptger3−/−, Ptger4−/−, Ptgfr−/−, Ptgir−/−, Tbxa2r−/−, Ltb4r1−/−, Ltb4r2−/−, Ptges−/−, Ptges2−/− and Alox15−/−; Supplementary Fig. 6a). Although Ltc4s−/− mice exhibited a lower PCA response as reported10, their ear histamine content was unaffected (data not shown). Thus, abnormalities in mast cells observed in mice lacking PLA2G3 were phenocopied only in mice lacking DP1.
Next we examined the expression and function of DP1 in a mast cell–fibroblast coculture system27. Although we barely detected Ptgdr mRNA in BMMCs and Swiss 3T3 fibroblasts, Ptgdr mRNA was robustly induced in Pla2g3+/+, but not in Pla2g3−/−, CTMC-like cells after coculture (Fig. 5f). Consistently, Ptgdr expression in the ear was lower in Pla2g3−/− mice than in Pla2g3+/+ mice (Fig. 5g). In agreement with the lower histamine amount in Ptgdr−/− dermal mast cells (Fig. 5d), the coculture-driven Hdc induction was severely impaired in Ptgdr−/− CTMC-like cells (Fig. 5h). In addition, the DP1 antagonist BW A868C prevented the coculture-induced upregulation of Hdc in wild-type CTMC-like cells (Fig. 5i). Conversely, the DP1 agonist BW 245C significantly enhanced Hdc induction in wild-type CTMC-like cells (Fig. 5j). However, the coculture-driven Hdc expression was barely restored by BW 245C in Pla2g3−/− mice (Fig. 5j), likely because DP1 induction was blunted by PLA2G3 deficiency (Fig. 5f). To circumvent this problem, we used the cAMP-elevating agent forskolin because DP1 is coupled with Gs-cAMP signaling9. The addition of forskolin to the coculture bypassed the requirement for DP1 in the induction of Hdc in Pla2g3−/− CTMC-like cells (Fig. 5k). By comparison, the expression of Ptgdr2, which encodes another PGD2 receptor known as CRTH2, was high in BMMCs and lowered in accordance with their maturation into CTMC-like cells, without being affected by the Pla2g3 genotypes (Supplementary Fig. 6b). Moreover, Hdc induction in CTMC-like cells was unaffected by CRTH2 deficiency in coculture, and Ptgdr2 expression was unaffected by PLA2G3 deficiency in vivo (Supplementary Fig. 6c,d). The coculture-driven production of other eicosanoids such as 15-HETE and PGI2 was unaffected by PLA2G3 deficiency (Supplementary Fig. 6e). Thus, DP1-cAMP signaling is specifically required for the PLA2G3-dependent maturation of mast cells.
We hypothesized that the absence of PGD2 biosynthetic enzyme(s), acting downstream of PLA2G3 and upstream of DP1, would also influence maturation of mast cells. Of the two PGD2 synthase–encoding genes, Ptgds2 (which encodes H-PGDS) was expressed in BMMCs but not in Swiss 3T3 fibroblasts, whereas Ptgds (which encodes lipocalin-type PGDS; L-PGDS) expression was higher in fibroblasts than in BMMCs (Fig. 6a) and was below the detection limit in pMCs (data not shown). L-PGDS immunoreactivity was associated with fibroblasts surrounding toluidine blue+ mast cells in mouse skin (Supplementary Fig. 7a). PCA was exacerbated in Ptgds2−/− mice30, which lack H-PGDS (Fig. 6b), whereas it was suppressed in Ptgds−/− mice31, which lack L-PGDS (Fig. 6c), in comparison with respective control mice. Ptgds−/− mice had fewer degranulated ear mast cells than did Ptgds+/+ mice after antigen challenge, although the total mast cell count was unaffected (Fig. 6d). Dermal mast cells in Ptgds−/− mice were ultrastructurally immature (that is, cytoplasmic granules were small and heterogeneous), comparatively resistant to antigen-induced degranulation, and contained less histamine than those in Ptgds+/+ mice (Fig. 6e,f). Thus, the notable similarity among Pla2g3−/−, Ptgds−/− and Ptgdr−/− mice suggests that PLA2G3, L-PGDS and DP1 may lie in the same regulatory pathway driving maturation of mast cells. The transfer of Ptgds+/+ or Ptgds−/− BMMCs into KitW-sh/W-sh mice fully restored the PCA response (Supplementary Fig. 7b), and a similar induction of Hdc occurred when Ptgds+/+ or Ptgds−/− BMMCs were cultured with fibroblasts (Supplementary Fig. 7c), indicating that L-PGDS in fibroblasts, not in mast cells, may be important for the regulation of mast cells.
Coculture with L-PGDS–silenced Swiss 3T3 fibroblasts by two distinct Ptgds-specific small interfering (si)RNAs resulted in less induction of Hdc in wild-type CTMC-like cells (Fig. 6g). PGD2 generation after coculture of parent fibroblasts with Pla2g3−/− BMMCs was ~50% lower than with Pla2g3+/+ BMMCs (Fig. 6h). The L-PGDS inhibitor AT-56 lowered PGD2 generation and Hdc induction in Pla2g3+/+ cocultures to amounts similar to those in Pla2g3−/− cocultures, although it did not affect these responses in Pla2g3−/− cocultures (Fig. 6h,i and Supplementary Fig. 7d). Hdc induction in wild-type BMMCs also occurred in coculture with primary skin fibroblasts from Ptgds+/+ mice, whereas this response was impaired in coculture with those from Ptgds−/− mice (Fig. 6j). Thus, the augmentative effects of PLA2G3 on coculture-driven synthesis of PGD2 and histamine were abrogated when L-PGDS in fibroblasts was ablated. L-PGDS–dependent production of PGD2, as revealed by coculture of Ptgds2−/− BMMCs with Swiss 3T3 fibroblasts, occurred gradually over a long period, whereas H-PGDS–dependent production of PGD2 was transient, albeit robust (Supplementary Fig. 7e), suggesting that the continuous supply of PGD2 by L-PGDS is crucial for maturation of mast cells.
Additionally, we observed robust upregulation of Ptgds2 in BMMCs and Ptgds in Swiss 3T3 fibroblasts or in primary mouse skin fibroblasts (and to a much lesser extent in BMMCs) in wild-type BMMC cocultures, whereas these responses occurred only partially in Pla2g3−/− BMMC cocultures (Supplementary Fig. 7f–h). Conversely, induction of Ptgds in Swiss 3T3 fibroblasts was enhanced in coculture with PLA2G3tg/+ BMMCs relative to wild-type BMMCs (Supplementary Fig. 7i). Thus, not only did mast cell–derived PLA2G3 supply arachidonic acid to L-PGDS in fibroblasts, it also contributed to induced expression of L-PGDS for efficient biosynthesis of a pool of PGD2 that promotes maturation of mast cells. However, addition of PLA2G3 or BV-PLA2 alone did not increase Ptgds expression in fibroblasts (Supplementary Fig. 7j), suggesting that some additional mast cell–derived factor(s) may be required for the induction of L-PGDS in fibroblasts. In agreement with the in vitro studies, amounts of PGD2 (Fig. 6k) and expression of two PGDSs (Fig. 6l) were significantly lower in the ear of Pla2g3−/− mice than that of Pla2g3+/+ mice, confirming the coupling of PLA2G3 with PGD2 synthesis in vivo. Thus, PLA2G3 secreted from mast cells is linked to fibroblastic L-PGDS–dependent synthesis of PGD2, which in turn activates DP1 induced on mast cells to assist their terminal maturation toward a fully anaphylaxis-sensitive CTMC-like phenotype (Supplementary Fig. 7k).
In human skin, toluidine blue+ dermal mast cells showed PLA2G3 immunoreactivity, although some toluidine blue− cells also appeared PLA2G3+ (Fig. 7a). We detected PLA2G3 mRNA expression in mast cells in preference to fibroblasts obtained from human lung and skin (Fig. 7b). HDC mRNA expression was robustly induced in human lung mast cells after coculture with human lung fibroblasts, and this induction was suppressed either by anti-PLA2G3, by L-PGDS inhibitor (AT-56) or by DP1 antagonist (BW A868C) to a similar extent (Fig. 7c). Thus, the fibroblast-dependent HDC induction in human mast cells also depends on the PLA2G3–L-PGDS–DP1 pathway.
Here we showed that PLA2G3, a major sPLA2 in mast cells, contributed to anaphylaxis by inducing maturation of mast cells in concert with adjacent fibroblasts through a unique pathway involving a cell-to-cell loop of the biosynthetic and receptor pathway for PGD2. Promotion of mast cell maturation by PGD2-DP1 signaling provides a mechanistic explanation for the protective effect of systemic DP1 ablation on asthma9. The paracrine PGD2 circuit driven by PLA2G3, an ‘anaphylactic sPLA2’, is a previously unidentified lipid-orchestrated pathway linked to allergy and uncovers a missing microenvironmental cue underlying the proper maturation of mast cells.
The SCF–c-Kit system, in cooperation with transcription factors, integrins or accessory cytokines, is essential for the development, homing, proliferation and differentiation of mast cells3–7. However, SCF alone is insufficient to drive the full maturation of mast cells, leading to the hypothesis that some other stromal factor(s) may be additionally required. These signals may include, for instance, interleukin 33, nerve growth factor, the morphogen TGF-β, hyaluronic acid and the adhesion molecule SgIGSF (spermatogenic immunoglobulin superfamily)3,4,7, although their in vivo relevancies have not yet been fully understood. As in mice lacking PLA2G3, mast cells in mice lacking histamine (Hdc−/−) or heparin (Ndst2−/− or Srgn−/−) are immature and have low histamine content32–34, suggesting that the lower amount of histamine may underlie, at least in part, the defective maturation of mast cells. We showed here that a signal driven by PGD2, a bioactive lipid, is a missing link required for the fibroblast-driven maturation of mast cells. The PLA2G3–L-PGDS–DP1 circuit revealed the paracrine action of sPLA2 in the biosynthetic mobilization of PGD2 by proximal cells, the functional segregation of the two PGDS enzymes in distinct cell populations and a new aspect of PGD2-DP1 signaling in promoting maturation of mast cells and thereby allergy. Moreover, our results revealed a previously unidentified aspect of the stromal cytokine SCF, which triggers this unique lipid-driven pathway by inducing PLA2G3 secretion from mast cells.
L-PGDS, a fibroblast-cell enzyme, acts downstream of PLA2G3 to supply PGD2 to DP1 in mast cells to drive their terminal maturation. Contrary to our prediction, PGD2 driven by H-PGDS, a mast cell enzyme, had an anti-allergy role, a view that is consistent with the exacerbated allergen-induced contact dermatitis in Ptgds2−/− mice11. Although it is unclear how the L-PGDS–driven extrinsic, but not the H-PGDS–driven intrinsic, pool of PGD2 is preferentially used by DP1 on mast cells, we speculate that the prolonged supply of PGD2 by L-PGDS, rather than its transient supply by H-PGDS, may be suitable for a long-lasting cell differentiation process. Alternatively, the PGD2 captured by L-PGDS, a lipid carrier protein (lipocalin), may be stabilized or better presented to mast cell DP1. This idea is reminiscent of a finding that lysophosphatidic acid (LPA), another lipid mediator, is presented to its cognate receptor as a complex with autotaxin, an LPA-producing enzyme35. The spatiotemporal discrimination of distinct PGD2 pools is also supported by the fact that although PGD2 promotes Th2-based asthma9, it contributes to resolution of inflammation through limiting neutrophil infiltration, dendritic cell activation or other mechanisms11–13.
The paracrine PLA2G3–L-PGDS–DP1 circuit could not be compensated by other PLA2 enzymes, implying a specific role of this atypical sPLA2. We observed no defects in maturation of mast cells or anaphylaxis even in mice lacking cPLA2α, although mild developmental changes in Pla2g4a−/− BMMCs have been reported, probably because of different culture conditions29. Presumably, ablation of only the specific and local lipid mediator pathway by PLA2G3 deficiency, in contrast to ablation of bulk eicosanoids in both mast cells and microenvironments by cPLA2α deficiency29, may have a different impact on mast cells. The phenotypes observed in Pla2g3−/− mice tend to be more severe than those observed in Ptgdr−/− or Ptgds−/− mice, suggesting that PLA2G3 might be also coupled with other lipid signal(s) that could act in concert with the L-PGDS–DP1 axis to promote full maturation of mast cells. Such lipid candidates include LPA and lysophosphatidylserine, which can affect mast cell development and activation36,37. Not only can lysophospholipids transmit signals through their specific receptors, but they can also facilitate the opening of Ca2+ channels, which might explain the degranulation-promoting effect of PLA2G3 on mast cells.
Although it has been proposed that sPLA2 enzymes, after being secreted, may act on neighboring cells or extracellular phospholipids to augment lipid mediator biosynthesis, this idea has yet to gain traction because in vivo evidence is largely lacking. Our study provides to our knowledge the first clear in vivo evidence that sPLA2 acts in this manner, thus providing a rationale for the long-standing question on the role of the secreted type of PLA2. This extracellular PLA2 family, through a paracrine process, regulates homeostasis and pathology in response to a given microenvironmental cue. Given that PLA2G3 is insensitive to classical sPLA2 inhibitors, a new agent that specifically inhibits this unique sPLA2 may be useful for the treatment of patients with mast cell–associated allergic and other diseases.
Pla2g3−/−, Pla2g4a−/−, Pla2g5−/−, Pla2g10−/−, Ptgdr−/−, Ptgdr2−/−, Ptgds−/−, Ptgds2−/−, Ptges−/−, Ptger1−/−, Ptger2−/−, Ptger3−/−, Ptger4−/−, Ptgfr−/−, Ptgir−/−, Tbxa2r−/−, Ltb4r1−/−, Ltb4r2−/−, Ltc4s−/−, Alox15−/− and PLA2G3tg/+ mice have been described previously9,14,17–19,22,26,38–44. Ptges2−/− mice (RIKEN RBRC04849) were generated by the Institute of Resource Development and Analysis (Kumamoto University). Pla2g2d−/−, Pla2g2e−/− and Pla2g2f−/− mice were generated by the Transgenic Resources Program (Department of Comparative Medicine, University of Washington; unpublished data). These mice were backcrossed to C57BL/6 mice for more than 11 generations, except for Pla2g3−/− and Ptger4−/− mice (129Sv × C57BL/6), which were from the third backcrosses to C57BL/6 mice owing to severe problems in reproduction22 and neonatal death39, respectively, particularly after successive backcrossing onto the C57BL/6 background. All experiments using knockout or transgenic mice (male, 8–12-week-old) were compared with their age-matched littermate control mice. Mast cell–deficient Kit mutant mice, C57BL/6J-KitW-sh/W-sh and WBB6F1-KitW/W-v, were purchased from the Jackson Laboratories and Japan SLC, respectively. All mice were housed in climate-controlled (23 °C) specific pathogen–free facilities with a 12-h light-dark cycle, with free access to standard laboratory food (CE2; CLEA) and water. All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committees of the Tokyo Metropolitan Institute of Medical Science and Showa University, in accordance with the Standards Relating to the Care and Management of Experimental Animals in Japan.
BV-PLA2 was purchased from Sigma-Aldrich. Recombinant mature human PLA2G3 protein was expressed in silkworms by the baculo-virus system and purified to near homogenity by an affinity column conjugated with mouse monoclonal anti–human PLA2G3 (5D2F1; IgG), as described previously26. PLA2 activities in the supernatants of mast cells were assayed by measuring the amounts of [14C]linoleic acid released from 1-palmitoyl-2-[14C]linoleoyl-phosphatidylethanolamine (Perkin Elmer). Each reaction mixture consisted of appropriate amounts of the samples, 100 mM Tris-HCl (pH 7.4), 4 mM CaCl2 and the substrate at 1 μM. After incubation for 2 h at 37 °C, [14C]linoleic acid was extracted, and the radioactivity was quantified with a liquid scintillation counter (LS5801; Beckman), as described previously22–24.
For PSA, mice were intravenously injected with 3 μg of monoclonal anti-DNP IgE (SPE-7; Sigma-Aldrich). After 24 h, the mice were challenged intravenously with 25 or 500 μg of DNP-conjugated human serum albumin (HSA; Sigma-Aldrich)27. Then, the rectal temperature was measured for 120 min with an electronic thermometer (Physitemp Instruments). For PCA, mice were passively sensitized by intradermal injection with 30 ng of anti-DNP IgE. After 24 h, the mice were challenged by intravenous injection of 20 or 60 μg of DNP-HSA in saline containing Evans blue dye (Wako)27. Extravasation of blue dye in the ear was monitored for 30 min, and ear biopsies were incubated at 37 °C in 3 N KOH. Quantitative analysis of the extracts was performed by measuring the absorbance of blue dye at 620 nm. For active anaphylaxis, mice were immunized intraperitoneally on days 0 (day when OVA was first administered), 7 and 14 with 10 μg of chicken OVA (Sigma-Aldrich) in 100 μl of saline mixed with 200 μl of alum (Alu Gel S, which contained 2% Al(OH)3; Serva). Seven days after the last immunization, the left and right ears of mice were injected intradermally with 30 μg of OVA. Net ear swelling was measured at 30 min after challenge with OVA.
The procedures were described previously27. Briefly, tissues were homogenized in PBS with a bead crusher (μT-01; Taitec) at 4 °C, and Triton X-100 was added to a final concentration of 0.5% (v/v). For the histamine assay, the lysates were treated with 3% (v/v) perchloric acid and left for 30 min on ice, and the resulting supernatants (tissue extracts) after centifugation at 10,000g for 30 min at 4 °C were applied to a cation-exchange WCX-1 column on HPLC (Shimadzu) to separate histamine, which was then measured fluorometrically by the o-phthalaldehyde method45. For the protease assay, 10 μl of the tissue extracts were diluted with 90 μl of 50 mM Tris-HCl (pH 8.3), followed by incubation with 20 μl of 1.8 mM chromogenic substrates for chymotrypsin- or trypsin-like proteases (S-2586 and S-2288, respectively; Chromogenix) and CPA (M-2245; Bachem) at 37 °C for 1–3 min. Changes in absorbance at 405 nm were measured.
To prepare BMMCs, mouse bone marrow (BM) cells were cultured in IL-3–containing BMMC complete medium27. After 4–6 weeks of culture, >97% of the cells were identified as Kit+FcεRIα+ mast cells by flow cytometry. The coculture-driven maturation of immature BMMCs toward CTMC-like cells has been described previously27. Briefly, BMMCs were seeded onto Swiss 3T3 fibroblast monolayer and cocultured for the appropriate durations (typically for 4 d) in the presence of mouse SCF (100 ng/ml; Peprotech). The cells were trypsinized and reseeded in culture dishes, and nonadherent cells were collected. Purity (>99%) was confirmed by flow cytometry for Kit and FcεRIα. Maturation of BMMCs into CTMC-like cells was verified by staining their granules with alcian blue and counterstaining with safranin O. As required for experiments, 10 μM AT-56, 1 μM BW A868C, 10 μM BW 245C (Cayman Chemical) or 10 μM forskolin (Sigma-Aldrich) were added to the coculture.
BM cells were cultured with mouse granulocyte-macrophage colony stimulating factor (GM-CSF; 10 ng/ml; Peprotech) for 9 d, mouse macrophage colony stimulating factor (M-CSF; 100 ng/ml; Kyowa Kirin) for 3 d or mouse TSLP (1 μg/ml; R&D Systems) for 5 d in RPMI1640 medium (Invitrogen) containing 10% (v/v) FBS (Invitrogen) to obtain BMDCs, BMDMs or BM basophils, respectively46,47. The purity of each cell population was verified by flow cytometry for the expression of CD11c and MHC class II for BMDCs, the expression of F4/80 and CD11b for BMDMs, and the expression of FcεRIα and CD200R3 (or DX5α) coupled with a lack of expression of Kit for BM basophils (see below).
BMMCs (106 cells) before and after coculture with fibroblasts were sensitized with 1 μg/ml anti-DNP IgE for 2 h and then stimulated with various concentrations (typically 100 ng/ml) of DNP-BSA (Sigma-Aldrich), 100 ng/ml mouse SCF or 10 μg/ml C48/80 (Sigma-Aldrich). Degranulation was evaluated by measuring histamine or β-HEX release, as described previously27. The levels of eicosanoids were determined by ELISA in accordance with the manufacturer’s instructions (Cayman Chemical). Expression of cytokines was assessed by real-time PCR. Lactate dehydrogenase activity was measured using an LDH Cytotoxicity Detection Kit (Takara).
To collect peritoneal cells, 5 ml of Hank’s balanced salt solution (Invitrogen) was injected into the mouse peritoneal cavity, and the abdomen was massaged gently. After collecting peritoneal cells from the peritoneal fluid, they were resuspended in PIPES-buffered saline for electron microscopy or in BMMC-complete medium for degranulation assay. For degranulation, 106 cells were treated for 30 min with 1–5 μg/ml of human PLA2G3 or BV-PLA2, with 1 μM A23187 (Sigma-Aldrich), or with 1 μg/ml anti-DNP IgE for 1 h and then with 100 ng/ml DNP-BSA for 30 min in the presence of 4 μM lysophosphatidylserine (Avanti Polar Lipids). The release of histamine was then evaluated.
Mouse ear skin was dispersed with 1.6 mg/ml collagenase type II (Worthington) and 0.1 mg/ml DNase I (Sigma-Aldrich) in RPMI1640 containing 10% FBS for 30 min at 37 °C and passed through a cell strainer (40-μm mesh size). Skin mast cells were identified as Kit+FcεRIα+ cells after CD45 gating by flow cytometry. The skin-dispersed cells were cultured in RPMI1640 containing 10% FBS, trypsinized and reseeded on culture dishes, and adherent cells grown to confluency were used as skin fibroblasts.
Preparation and culture of mast cells from human skin and lung were performed as described previously48. Briefly, macroscopically normal human lung or skin tissue was obtained during surgery at the Nihon University Hospital under approval of the faculty ethics committee and informed consent from the patient. Lung and skin cells were dispersed from chopped lung and foreskin specimens by collagenase and hyaluronidase (Sigma-Aldrich). These cells were maintained for 6 weeks in MethoCult SFBIT (Iscove’s modified Dulbecco’s medium (IMDM)-based serum-free medium containing 1.2% (w/v) methylcellulose; Veritas) supplemented with human SCF (100 ng/ml; Peprotech) and human IL-6 (50 ng/ml; Peprotech). On day 42, methylcellulose was dissolved in PBS, and the cells were resuspended and cultured in IMDM medium (Invitrogen) containing 0.1% BSA, 100 ng/ml SCF and 50 ng/ml IL-6. The purity of human mast cells, as assessed with metachromatic staining, was more than 97%. Human skin and lung fibroblasts (CC-2511 and CC-2512, respectively) and their culture medium were purchased from Lonza. Human lung mast cells (5 × 105 cells) were seeded onto the human lung fibroblast monolayer and cocultured for 4 d in 500 μl of IMDM medium plus 2% FBS in the presence of SCF and IL-6, with medium change at 2-d intervals. The cells were trypsinized and reseeded in culture dishes, and nonadherent cells were collected. The purity of mast cells was normalized based on the expression of KIT.
Total RNA was extracted from tissues and cells using TRIzol reagent (Invitrogen). First-strand cDNA synthesis was performed using the High-Capacity cDNA Reverse-Transcriptase Kit (Applied Biosystems). PCRs were carried out using the TaqMan Gene Expression System (Applied Biosystems) on an ABI7700 Real-Time PCR system (Applied Biosystems). The probe-primer sets are listed in Supplementary Table 2.
Intracellular Ca2+ levels were measured as described previously27. Briefly, IgE-sensitized BMMCs on coverslips were loaded for 60 min with the fluorescent Ca2+ indicator fura-2/AM (5 μM; Invitrogen) in Tyrode-HEPES buffer (pH 7.4) containing 2.5 mM probenecid, 0.04% (v/v) pluronic acid and 1% (v/v) serum. Then, the cells were washed and stimulated with antigen. Fura-2 fluorescence images were obtained using an image analyzer (ARGUS-50; Hamamatsu Photonics) with excitation at 340 nm (F340) and 380 nm (F380) at 5-s intervals. The fluorescence ratio (F340/F380) was calculated using US National Institutes of Health ImageJ software.
Tissue homogenates (20 μg protein equivalent) or BMMCs (2 × 105 cells) were lysed in SDS-PAGE sample buffer (63 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, and 0.08% (w/v) bromophenol blue) containing 5% (v/v) 2-mercaptoethanol, and then subjected to SDS-PAGE. Proteins were subsequently blotted onto PVDF membranes (Bio-Rad), followed by blocking with 5% (w/v) milk powder in PBS containing 0.05% (v/v) Tween 20 (PBS-T). The membranes were probed with rabbit polyclonal antibodies to HDC49, H-PGDS30, Kit (18101; IBL), PLCγ2 (3872; Cell Signaling), phospho-PLCγ2 Y1217 (3871; Cell Signaling), cPLA2α (2832; Cell Signaling) or phospho-cPLA2α S505 (2831; Cell Signaling) or mouse monoclonal antibodies against Akt (D9E; Cell Signaling), phospho-Akt S473 (C67E7; Cell Signaling), ERK1/2 (MK12; BD Transduction Laboratories), phospho-ERK1/2 T202/Y204 (20A; BD Transduction Laboratories), JNK (37; BD Transduction Laboratories), phospho-JNK T183/Y185 (41; BD Transduction Laboratories), p38 (27; BD Transduction Laboratories) or phospho-p38 MAPK T180/Y182 (30; BD Transduction Laboratories) at 1:500–1:2,000 dilutions in PBS-T containing 1% (w/v) milk powder or in Can Get Signal Solution 1 (Toyobo) for 1.5 h. After membranes were washed, the membranes were incubated for 1 h with horseradish peroxidase (HRP)-conjugated anti-rabbit (AP156P; Chemicon) or anti-mouse (21040; Molecular Probes) IgG at 1:5,000 dilution in PBS-T containing 1% milk powder or in Can Get Signal Solution 2 (Toyobo), and then visualized with ECL Prime western blotting detection reagent (GE Healthcare Life Science) on LAS-4000 (Fuji Film).
Ears were fixed in 10% (v/v) neutral buffered formalin, embedded in paraffin and cut using a microtome. The sections (4 μm thickness) were stained with 0.05% toluidine blue (pH 0.5) for the detection of mast cells. Degranulated mast cells were defined as those showing the release of cellular granules. For immunohistochemistry, sections were incubated in PBS containing 5% normal goat serum, 5% BSA and 0.025% Triton X-100 for 20 min and then immunostained with a rabbit polyclonal to human PLA2G3, which reacts with both mature human and mouse enzymes (whose homology is 83%)22–24, and mouse L-PGDS50, at dilutions of 1:200 and 1:1,000, respectively, in the same buffer at 4 °C overnight. These preparations were incubated with biotinylated goat anti-rabbit IgG (BA-1000; Vector Laboratories) in PBS containing 5% BSA, 0.025% Triton X-100 and 10% mouse serum for 30 min followed by incubation with avidin DH and biotinylated HRP (Vectastain ABC kit; Vector Laboratories). These preparations were stained with 0.5 mg/ml 3,3′-diaminobenzidine and 0.1% (v/v) hydrogen peroxide solution. Human tissue sections were obtained from Chiba University following approval by the faculty ethical committee and informed consent from the patient. For transmission microscopy, tissues or cells were fixed with 0.1 M sodium cacodylate buffer (pH 7.2) containing 1% (v/v) glutaraldehyde and 4% (w/v) paraformaldehyde, postfixed with 2% (w/v) OsO4 in PBS, dehydrated by a graded ethanol series, passed through propylene oxide and embedded in Poly/Bed812 EPON (Polyscience). Ultrathin sections (0.08-μm thickness) were stained with uranyl acetate and lead citrate and then examined using an electron microscope (H-7600; Hitachi).
BMMCs obtained from 8–12-week-old male mice were reconstituted by intradermal (106 cells) or intravenous (107 cells) injection into 6-week-old male KitW-sh/W-sh mice. Six weeks after intradermal transfer or 12 weeks after intravenous transfer of BMMCs, the mice were subjected to IgE-Ag–induced PCA, as described above. Alternatively, mast cells from the base to the tip of the ears from these mice were evaluated by toluidine blue staining or by real-time PCR of mast cell marker genes.
Cells were stained with either a labeled monoclonal antibody or an isotype-matched control antibody (hamster IgG (HTK888), mouse IgG1 (MOPC-21), rat IgG2a (RTK2758) or rat IgG2b (RTK4530); BioLegend) and analyzed by flow cytometry using FACSCalibur (BD Biosciences) or FACSAria III Cell Sorter (BD Biosciences) with FlowJo software (Tree Star). The antibodies used were specific for mouse Kit (2B8; BD Biosciences), FcεRIα (MAR-1; eBioscience), DX5 (DX5; eBioscience), CD200R3 (Ba13; BioLegend), CD45 (30-F11; eBioscience), CD11c (N418; eBioscience), MHC class II (M5/114.15.2; eBioscience), CD11b (M1/70; BioLegend), F4/80 (BM8; BioLegend), CD45R/B220 (RA3-6B2; BD Biosciences), CD3ε (145-2X11; eBioscience), Gr-1 (RB-8C5; BioLegend), FOXP3 (150D; BioLegend) and FR4 (12A5; BioLegend).
Total RNA was extracted from BMMCs derived from Pla2g3−/− and Pla2g3+/+ mice before and after coculture and purified using the RNeasy Mini Kit (Qiagen). The quality of RNA was assessed with a 2100 Bioanalyzer (Agilent Technologies). Both cDNA and cRNA were synthesized with a Low Input Quick Amp Labeling Kit according to the manufacturer’s protocol (Agilent Technologies). Samples were hybridized to the Whole Mouse Genome Microarray Kit (4 × 44K; Agilent Technologies), washed and then scanned using a Laser Scanner GenePix 4000B (Molecular Devices). Microarray data were analyzed with Feature Extraction software (Agilent Technologies) and then imported into GeneSpringGX11.5 (Agilent Technologies). Probes were normalized by quantile normalization among all microarray data.
Swiss 3T3 fibroblasts were cultured in 12-well plates to 50% confluence and transfected with a Mission predesigned siRNA construct (20 nM) for Ptgds (SASI_Mm01_00116073 or 00116081; Sigma-Aldrich) or a scrambled control siRNA (Invitrogen) using oligofectamine (Invitrogen), according to the manufacturer’s instructions. After 48 h, wild-type BMMCs were cocultured for 2 d with the transfected cells.
ESI-MS lipidomics analysis using a 4000Q TRAP quadrupole-linear ion trap hybrid mass spectrometer (AB SCIEX) with an UltiMate 3000 nano/cap/micro-liquid chromatography system (Dionex Corporation) combined with an HTS PAL autosampler (CTC Analytics AG) was performed as described previously44. Briefly, phospholipids extracted from 107 BMMCs were subjected directly to ESI-MS analysis by flow injection; typically, 3 μl (3 nmol phosphorous equivalent) of sample was applied. The mobile phase composition was acetonitrile/methanol/water (v/v/v = 6/7/2) plus 0.1% (v/v) ammonium formate (pH 6.8) at a flow rate of 10 μl/min. The scan range of the instrument was set at m/z 200–1,000 at a scan speed of 1,000 Da/s. The trap fill-time was set at 3 ms in the positive ion mode and at 5 ms in the negative ion mode. The ion spray voltage was set at 5,500 V in the positive ion mode and at −4,500 V in the negative ion mode. Nitrogen was used as a curtain gas (at a setting of 10 arbitrary units) and as a collision gas (set to ‘high’).
The Excel Statistical Program File ystat 2008 (Igaku Tosho Shuppan) was used to determine statistical significance evaluated by an unpaired Student’s t-test for two groups or an analysis of variance (ANOVA) for multiple groups. P values of less than 0.05 and 0.01 were considered statistically significant. Data are presented as the mean ± s.e.m.
We thank Y. Tanoue, H. Ohkubo, K. Araki and K. Yamamura for generating Ptges2−/− mice. This work was supported by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22116005 and 24390021 to M.M. and 23790119 and 24117724 to Y.T.), Promoting Individual Research to Nurture the Seeds of Future Innovation and Organizing Unique Innovative Network (PRESTO) of Japan Science and Technology Agency (to M.M.), and the Uehara, Mitsubishi, Terumo, Mochida and Toray Science Foundations (to M.M.).
Accession code. Gene Expression Ominibus: GSE44980 (microarray data).
Note: Supplementary information is available in the online version of the paper.
AUTHOR CONTRIBUTIONSY.T. performed experiments and together with M.M. conceived and designed the study, interpreted the findings and wrote the manuscript; N.U., T.K., M.K., R.M. and H.S. performed experiments; S.T., M.S., Masanori Nakamura, Y.N., K.I., K.M., Satoshi Nakamizo, K.K., Y.O. and C.R. helped perform some experiments; K.Y., N.K., R.T., M.H.G. M.A., T.Y., Masataka Nakamura, K.W., H.H., Motonao Nakamura, K.A., Y.U., Y.S., T.S., Shu Narumiya and S.H. contributed to experimental designs.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.